PL4284356T3 - Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi - Google Patents
Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagiInfo
- Publication number
- PL4284356T3 PL4284356T3 PL22708379.7T PL22708379T PL4284356T3 PL 4284356 T3 PL4284356 T3 PL 4284356T3 PL 22708379 T PL22708379 T PL 22708379T PL 4284356 T3 PL4284356 T3 PL 4284356T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- treatment
- attention deficit
- hyperactivity disorder
- deficit hyperactivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2101291.9A GB202101291D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101292.7A GB202101292D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101296.8A GB202101296D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| PCT/EP2022/052142 WO2022162199A2 (en) | 2021-01-29 | 2022-01-28 | Novel treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4284356T3 true PL4284356T3 (pl) | 2025-07-28 |
Family
ID=80682355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22708379.7T PL4284356T3 (pl) | 2021-01-29 | 2022-01-28 | Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240130995A1 (pl) |
| EP (1) | EP4284356B1 (pl) |
| JP (1) | JP2024508372A (pl) |
| AU (1) | AU2022215118A1 (pl) |
| CA (1) | CA3206935A1 (pl) |
| ES (1) | ES3038949T3 (pl) |
| HR (1) | HRP20250747T1 (pl) |
| HU (1) | HUE071725T2 (pl) |
| PL (1) | PL4284356T3 (pl) |
| RS (1) | RS66934B1 (pl) |
| SM (1) | SMT202500238T1 (pl) |
| WO (1) | WO2022162199A2 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025093748A1 (en) * | 2023-11-03 | 2025-05-08 | 3Z Pharmaceuticals | Use of a calcium channel blocker in the treatment of adhd |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030672A1 (en) * | 1997-11-19 | 2000-08-30 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| JP2007512339A (ja) * | 2003-11-21 | 2007-05-17 | メモリー・ファーマシューティカルズ・コーポレイション | 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用 |
| EP1609783A1 (en) * | 2004-06-17 | 2005-12-28 | Neuropharma S.A.U. | Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment |
| WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
| WO2011100659A2 (en) * | 2010-02-12 | 2011-08-18 | Kitov Pharmaceutical Ltd. | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
| SI2895507T1 (sl) * | 2012-09-11 | 2019-03-29 | Institucio Catalana De Recerca I Estudis Avancats | Diagnostični postopek za detektiranje avtoimunske bolezni in povezane zadeve |
| WO2014133329A1 (ko) * | 2013-02-27 | 2014-09-04 | 에스케이케미칼 주식회사 | 관절염 치료용 복합 제제 |
| KR20140135676A (ko) * | 2014-10-02 | 2014-11-26 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| CA3084425A1 (en) * | 2017-10-27 | 2019-05-02 | Esteve Pharmaceuticals, S.A. | New alcoxyamino derivatives for treating pain and pain related conditions |
| WO2020120606A1 (en) * | 2018-12-12 | 2020-06-18 | Esteve Pharmaceuticals, S.A. | New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions |
-
2022
- 2022-01-28 EP EP22708379.7A patent/EP4284356B1/en active Active
- 2022-01-28 PL PL22708379.7T patent/PL4284356T3/pl unknown
- 2022-01-28 ES ES22708379T patent/ES3038949T3/es active Active
- 2022-01-28 AU AU2022215118A patent/AU2022215118A1/en active Pending
- 2022-01-28 HR HRP20250747TT patent/HRP20250747T1/hr unknown
- 2022-01-28 CA CA3206935A patent/CA3206935A1/en active Pending
- 2022-01-28 SM SM20250238T patent/SMT202500238T1/it unknown
- 2022-01-28 HU HUE22708379A patent/HUE071725T2/hu unknown
- 2022-01-28 RS RS20250624A patent/RS66934B1/sr unknown
- 2022-01-28 WO PCT/EP2022/052142 patent/WO2022162199A2/en not_active Ceased
- 2022-01-28 JP JP2023546027A patent/JP2024508372A/ja active Pending
- 2022-01-28 US US18/274,945 patent/US20240130995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS66934B1 (sr) | 2025-07-31 |
| EP4284356B1 (en) | 2025-04-02 |
| SMT202500238T1 (it) | 2025-07-22 |
| AU2022215118A1 (en) | 2023-08-17 |
| AU2022215118A9 (en) | 2024-05-16 |
| WO2022162199A3 (en) | 2022-09-15 |
| WO2022162199A2 (en) | 2022-08-04 |
| CA3206935A1 (en) | 2022-08-04 |
| EP4284356C0 (en) | 2025-04-02 |
| JP2024508372A (ja) | 2024-02-27 |
| ES3038949T3 (en) | 2025-10-16 |
| HUE071725T2 (hu) | 2025-09-28 |
| EP4284356A2 (en) | 2023-12-06 |
| HRP20250747T1 (hr) | 2025-08-15 |
| US20240130995A1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290415A (en) | Compounds with deuterium for use in cancer treatment | |
| IL272597B (en) | Pyruvate kinase activators for use in the treatment of blood disorders | |
| LT3435996T (lt) | Elafibranolas, skirtas panaudoti gydant pirminį tulžies latakų cholangitą | |
| IL266764A (en) | Gaboxadol for use in methods of treating attention deficit/hyperactivity disorder | |
| EP3054935A4 (en) | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions | |
| PL3496733T3 (pl) | Kompozycja do stosowania w leczeniu dużego zaburzenia depresyjnego | |
| IL261418A (en) | Mazindol immediate-release/delayed-release multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| SMT202500238T1 (it) | Composti per l’uso nel trattamento di disturbo da iperattività e deficit di attenzione | |
| RS67403B1 (sr) | Sotorasib za upotrebu u lečenju kancera | |
| EP2806736A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT | |
| PT2844277T (pt) | Resumo | |
| IL278763A (en) | Methods for treating attention deficit hyperactivity disorder | |
| PL4146225T3 (pl) | Związki metylotioniniowe do zastosowania w leczeniu hipoksemii | |
| MX2016014780A (es) | Metodos y composiciones de dasotralina para el tratamiento del adhd. | |
| HUE066554T2 (hu) | Keverõ egység szennyvízkezelõ berendezésekben kezelt folyadékok keveréséhez | |
| IL284953A (en) | Methylphenidate compositions for treatment of attention deficit hyperactivity disorder | |
| MX2016014768A (es) | Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. | |
| IL232897B (en) | Pacetopran for the treatment of attention, concentration and hyperactivity disorder | |
| BRPI1014545A2 (pt) | composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade | |
| EP4389126A4 (en) | Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder | |
| SI3082798T1 (sl) | Benzodioksolni derivati za uporabo pri zdravljenju pomanjkanja pozornosti in/ali hiperaktivnosti | |
| GB201415260D0 (en) | Aerator For Use in sewage treatment | |
| GB201415259D0 (en) | Aerator for use in sewage treatment |